Market Position Clause Samples

Market Position. Because it is the "first of its kind", OncoScint CR/OV has been a difficult product to market. Nuclear physicians as well as referring physicians are still learning how to actually use the product and to interpret the information obtained from the scan. Cytogen sees several contingencies that may improve the use of OncoScint CR/OV in the commercial setting and, in turn, increase sales. These include: [Information omitted and filed separately with the Commission under Rule 24b-2. OncoScint CR/OV is available through the nuclear medicine department of the patient's hospital and is administered on an outpatient basis. The process is safe and painless - OncoScint CR/OV and the isotope are injected and the scanning procedure is completed between 24-120 hours later. Results are available immediately.

Market Position. 8.1.1. General Trends of the EDA Market (system and RT level)

Market Position. The Company is not in a dominant position in a market in the European Communities or European Economic Area, or a substantial part of a market in the European Communities or European Economic Area, for the purposes of Article 82 of the Treaty of Rome and Article 54 of the Agreement on the European Economic Area.

Market Position. DCC is the leading manufacturer of silicone-based products worldwide. DCC believes that it is positioned within the industry to maintain or, with respect to certain applications and business lines, increase its worldwide segment share over the Projection Period as a result of its reputation and commitment to innovation, globalization of the silicone industry and anticipated increases in demand for silicone-based products.